| BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat) |
RESEARCH TRIANGLE PARK, N.C., May 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) in adolescents and people with severe HAE showing significant and sustained reductions in HAE attack rates through 18 months of follow-up after beginning treatment with ORLADEYO in both patient populations. |
globenewswire.com |
2025-05-16 11:00:00 |
Czytaj oryginał (ang.) |
| HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up |
Haemonetics' fourth-quarter fiscal 2025 results reflect the positive impact of its long-term plan, with meaningful earnings growth and margin expansion. |
zacks.com |
2025-05-12 13:40:46 |
Czytaj oryginał (ang.) |
| Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4 |
Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedema Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedema |
globenewswire.com |
2025-05-12 10:50:00 |
Czytaj oryginał (ang.) |
| Haemonetics Corporation (HAE) Q4 2025 Earnings Call Transcript |
Haemonetics Corporation (NYSE:HAE ) Q4 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Olga Guyette – Vice President-Investor Relations & Treasury Chris Simon – Chief Executive Officer James D'Arecca – Chief Financial Officer Conference Call Participants Rohin Patel – JPMorgan Marie Thibault – BTIG Mike Matson – Needham & Company Andrew Cooper – Raymond James Joanne Wuensch – Citi Anthony Petrone – Mizuho Financial Group Michael Petusky – Barrington Research Craig Bijou – Bank of America Securities Operator Good day, and thank you for standing by. Welcome to the Q4 2025 Haemonetics Corporation Earnings Conference Call. |
seekingalpha.com |
2025-05-10 17:05:28 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings |
The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-10 01:30:36 |
Czytaj oryginał (ang.) |
| Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates |
Haemonetics (HAE) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $0.90 per share a year ago. |
zacks.com |
2025-05-08 14:20:39 |
Czytaj oryginał (ang.) |
| Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website |
Financial release accessible online BOSTON , May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. |
prnewswire.com |
2025-05-08 10:00:00 |
Czytaj oryginał (ang.) |
| Gear Up for Haemonetics (HAE) Q4 Earnings: Wall Street Estimates for Key Metrics |
Besides Wall Street's top -and-bottom-line estimates for Haemonetics (HAE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025. |
zacks.com |
2025-05-07 14:21:12 |
Czytaj oryginał (ang.) |
| Haemonetics (HAE) Earnings Expected to Grow: Should You Buy? |
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-01 15:05:46 |
Czytaj oryginał (ang.) |
| 4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates |
MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release. |
zacks.com |
2025-05-01 12:30:38 |
Czytaj oryginał (ang.) |
| New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies |
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced results from a new survey showing that 91% of surveyed adults living with hereditary angioedema (HAE) were interested in trying a new prophylactic therapy, with nearly two-thirds (65%) reporting they haven't yet found the best treatment option for them. The Ionis-sponsored survey was conducted online by The Harris Poll among 150 adults living with HAE and 228 allergists/immunologists who see HAE patien. |
businesswire.com |
2025-04-29 11:00:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has licensed commercialization rights in Japan to Kaken Pharmaceutical, Co., Ltd. (JPX: 4521.T) for sebetralstat, an investigational, oral on-demand treatment for hereditary angioedema (HAE). KalVista will receive an upfront payment of $11 million, with an additional payment of up to $11 million upon achievement o. |
businesswire.com |
2025-04-08 10:30:00 |
Czytaj oryginał (ang.) |
| Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025 |
BOSTON , March 31, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET on Thursday, May 8, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 8, 2025. |
prnewswire.com |
2025-03-31 20:00:00 |
Czytaj oryginał (ang.) |
| KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial |
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of sebetralstat, an investigational, novel, oral plasma kallikrein inhibitor, in pediatric patients between the ages of two and 11 with hereditary angioedema (HAE). “We're proud to share that we achieved target enrollment in our KONFIDENT-KID trial a full year ahead of schedule and expanded the trial siz. |
businesswire.com |
2025-03-25 09:00:00 |
Czytaj oryginał (ang.) |
| Is it Apt to Retain HAE Stock in Your Portfolio for Now? |
Strong prospects for the Hospital Business and the robust NexSys PCS system bode well for Haemonetics. |
zacks.com |
2025-03-18 13:40:22 |
Czytaj oryginał (ang.) |
| Haemonetics Announces Executive Leadership Updates |
Frank Chan joins Haemonetics as Executive Vice President, Chief Operating Officer; Roy Galvin named Executive Vice President, Chief Commercial Officer BOSTON , March 3, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced updates to its Executive Leadership team. Frank Chan, Ph.D. |
prnewswire.com |
2025-03-03 18:10:00 |
Czytaj oryginał (ang.) |
| Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress |
ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), highlighted safety and efficacy data of deucrictibant, which is currently being evaluated in two pivotal Phase 3 studies, following long-term dosing in the prophylactic and on-demand settings at the American Academy of Allergy, Asthma, & Immunology's Annual Scientific Meeting (AAAAI) and World Allergy Organization (WAO) Joint Congress, which was held from February 28–March 3, 2025, in San Diego, CA. |
globenewswire.com |
2025-03-03 08:50:00 |
Czytaj oryginał (ang.) |
| Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference |
BOSTON , Feb. 24, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025 at 2:50 p.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://wsw.com/webcast/rj131/hae/1437678. |
prnewswire.com |
2025-02-24 08:00:00 |
Czytaj oryginał (ang.) |
| The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) |
TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pen Option is Designed to Allow for An Individualized Treatment Approach for Adolescent and Adult HAE Patients. In the EU, TAKHZYRO is Approved for Routine Prevention of Recurrent HAE Attacks in Patients Aged 2 Years and Older.1 ZURICH , Feb. 24, 2025 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab) for subcutaneous administration in adolescents (aged 12 years and above) and adult patients with Hereditary Angioedema (HAE).1 The additional subcutaneous administration option expands Takeda's offering in this space, showing dedication to the HAE community while providing individualized treatment options to support patients with a life-threatening disease, by helping to reduce HAE burden and improving their Quality of Life. |
prnewswire.com |
2025-02-24 05:01:00 |
Czytaj oryginał (ang.) |
| CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) |
ANDEMBRY® is a first-in-class monoclonal antibody treatment that inhibits activated Factor XII (FXIIa), the initiating factor in the HAE pathway, and offers the first pre-filled pen presentation enabling once-monthly subcutaneous administration The approval is based on the results of the international pivotal Phase 3 VANGUARD trial, which included HAE patients from Japan CSL is dedicated to improving the lives of those with HAE – a community that we have proudly supported for more than 40 years TOKYO , Feb. 20, 2025 /PRNewswire/ -- CSL Behring K.K. (Headquarters: Minato-ku, Tokyo; President and Representative Director: Izumi Yoshida) today announced that it has received manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for ANDEMBRY® (garadacimab) Subcutaneous (S.C. |
prnewswire.com |
2025-02-20 11:13:00 |
Czytaj oryginał (ang.) |
| Astria Therapeutics: A High-Conviction Bet On HAE |
Astria Therapeutics' strong cash position and efficient spending provide a financial runway through mid-2027, reducing dilution risk and supporting pivotal trials for navenibart and STAR-0310. Navenibart, targeting hereditary angioedema, shows promising Phase 1b/2 data with a 90-95% reduction in attack rates, positioning it as a potential best-in-class treatment. STAR-0310, aimed at atopic dermatitis, leverages OX40 inhibition and YTE half-life extension technology, though it faces stiff competition and must prove differentiation. |
seekingalpha.com |
2025-02-18 00:32:44 |
Czytaj oryginał (ang.) |
| European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) |
- ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits plasma protein factor XIIa, which initiates the cascade of events leading to angioedema at various sites of the body- ANDEMBRY reinforces CSL's decades-long commitment to delivering innovative treatment modalities to the HAE community and comes with a convenient patient-centric pre-filled pen (auto-injector) enabling subcutaneous self-injection- Supported by the Phase 3 VANGUARD trial, this marks the third regulatory approval for ANDEMBRY, which was also recently approved by Australia's Therapeutic Goods Administration (TGA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) in January MARBURG, Germany, Feb. 13, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the European Commission (EC) has approved ANDEMBRY® (garadacimab), the first and only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older. ANDEMBRY inhibits plasma protein factor XIIa, which initiates the cascade of events leading to angioedema at various sites of the body. |
prnewswire.com |
2025-02-13 09:00:00 |
Czytaj oryginał (ang.) |
| HAE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket |
Haemonetics' third-quarter fiscal 2025 results reflect the positive effects of the company's long-range plan with meaningful earnings growth and margin expansion. |
zacks.com |
2025-02-07 12:16:18 |
Czytaj oryginał (ang.) |
| Haemonetics Corporation (HAE) Q3 2025 Earnings Call Transcript |
Haemonetics Corporation (NYSE:HAE ) Q3 2025 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants Olga Guyette - Vice President, Investor Relations and Treasury Christopher Simon - President and Chief Executive Officer James D'Arecca - EVP and Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Financial Group Marie Thibault - BTIG David Turkaly - Citizens JMP Andrew Cooper - Raymond James Mike Matson - Needham & Company Craig Bijou - Bank of America Securities Michael Petusky - Barrington Research Larry Solow - CJS Securities Operator Good day, and welcome to the Haemonetics Third Quarter Fiscal Year 2025 Conference Call and Webcast. At this time, all participants are in a listen-only-mod. |
seekingalpha.com |
2025-02-06 14:19:40 |
Czytaj oryginał (ang.) |
| Haemonetics (HAE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates |
Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-06 12:36:39 |
Czytaj oryginał (ang.) |
| Haemonetics (HAE) Q3 Earnings Meet Estimates |
Haemonetics (HAE) came out with quarterly earnings of $1.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.04 per share a year ago. |
zacks.com |
2025-02-06 10:41:17 |
Czytaj oryginał (ang.) |
| Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website |
Financial release accessible online BOSTON , Feb. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2025, which ended December 28, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. |
prnewswire.com |
2025-02-06 08:00:00 |
Czytaj oryginał (ang.) |
| Here's Why Haemonetics (HAE) is a Strong Value Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-01-24 12:41:28 |
Czytaj oryginał (ang.) |
| HAE or ABT: Which Is the Better Value Stock Right Now? |
Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2025-01-20 14:40:23 |
Czytaj oryginał (ang.) |
| Completion of Whole Blood Assets Sale to GVS Likely to Boost HAE Stock |
Haemonetics completes the sale of whole blood assets to GVS, S.p.A. |
zacks.com |
2025-01-20 11:06:09 |
Czytaj oryginał (ang.) |
| Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A |
BOSTON , Jan. 14, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has completed the previously announced sale of its whole blood assets to GVS, S.p.A ("GVS"), one of the world's leading manufacturers of filter solutions for applications in the healthcare and life sciences sectors. In connection with the closing of this transaction, GVS has acquired Haemonetics' portfolio of proprietary whole blood collection, processing and filtration solutions, along with Haemonetics' manufacturing facility in Covina, California where certain of these products are produced, and related equipment and assets located at Haemonetics' manufacturing facility in Tijuana, Mexico. |
prnewswire.com |
2025-01-14 08:13:00 |
Czytaj oryginał (ang.) |
| Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2025 Results: February 6, 2025 |
BOSTON , Jan. 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, February 6, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 6, 2025. |
prnewswire.com |
2025-01-08 19:03:00 |
Czytaj oryginał (ang.) |
| Why Haemonetics (HAE) is a Top Value Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-01-08 12:41:20 |
Czytaj oryginał (ang.) |
| Haemonetics to Present at 43rd Annual J.P. Morgan Healthcare Conference |
BOSTON , Jan. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 5:15 pm Pacific Time. |
prnewswire.com |
2025-01-06 08:00:00 |
Czytaj oryginał (ang.) |
| HAE vs. ABT: Which Stock Is the Better Value Option? |
Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now? |
zacks.com |
2025-01-03 14:51:09 |
Czytaj oryginał (ang.) |
| 5 Beaten-Down MedTech Stocks Set to Rebound in 2025 |
Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape. |
zacks.com |
2024-12-30 11:25:28 |
Czytaj oryginał (ang.) |
| Here's Why You Should Add HAE Stock to Your Portfolio Now |
Strong prospects for the Plasma franchise and favorable solvency bode well for Haemonetics. |
zacks.com |
2024-12-24 10:46:08 |
Czytaj oryginał (ang.) |
| Down -11.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Haemonetics (HAE) |
The heavy selling pressure might have exhausted for Haemonetics (HAE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2024-12-23 12:36:10 |
Czytaj oryginał (ang.) |
| KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025 |
NDA submission of sebetralstat was accepted for review by the FDA as an on-demand treatment option for HAE patients, with a PDUFA review date of June 17th of 2025. If sebetralstat is approved by the FDA, it would be the first and only on-demand oral treatment for HAE patients ages 12 and older. The global Hereditary Angioedema treatment market size is projected to reach $17.31 billion by the end of 2032. |
seekingalpha.com |
2024-12-18 15:46:24 |
Czytaj oryginał (ang.) |
| HAE or SYK: Which Is the Better Value Stock Right Now? |
Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2024-12-18 14:40:43 |
Czytaj oryginał (ang.) |
| CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE) |
If approved, garadacimab will be the first and only once-monthly treatment inhibiting factor XIIa to prevent attacks in HAE patients – a community CSL has been serving for more than 40 years MARBURG, Germany , Dec. 13, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting a marketing authorization for garadacimab as a once-monthly prophylactic treatment for hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older. Garadacimab is a monoclonal antibody that targets activated factor XII (factor XIIa), a plasma protein that plays a key role in attacks of swelling in people with HAE, thereby inhibiting the HAE cascade at the top to prevent HAE attacks. |
prnewswire.com |
2024-12-13 12:38:00 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing Haemonetics (HAE) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-12-06 12:41:18 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 27.84% Upside in Haemonetics (HAE): Can the Stock Really Move This High? |
The average of price targets set by Wall Street analysts indicates a potential upside of 27.8% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-12-04 12:56:13 |
Czytaj oryginał (ang.) |
| Will HAE Stock Gain Following Sell-Off of Whole Blood Assets to GVS? |
Haemonetics inks a new agreement to sell its whole blood assets to GVS. The transaction is expected to be closed in the first quarter of 2025. |
zacks.com |
2024-12-04 12:51:28 |
Czytaj oryginał (ang.) |
| 4 Medical Product Stocks to Buy From a Prospective Industry |
An ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. RMD, HAE, PAHC and AGIO are well-poised to gain from the favorable factors. |
zacks.com |
2024-12-04 12:45:35 |
Czytaj oryginał (ang.) |
| Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A |
BOSTON , Dec. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to sell its whole blood assets to GVS, S.p.A ("GVS"), one of the world's leading manufacturers of filter solutions for applications in the healthcare and life sciences sectors. The transaction comprises a total cash consideration of up to $67.1M, which includes $44.6M upfront and up to $22.5M in contingent earn-outs over the next four years. |
prnewswire.com |
2024-12-03 03:16:00 |
Czytaj oryginał (ang.) |
| HAE or BSX: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2024-11-15 14:40:20 |
Czytaj oryginał (ang.) |
| Here's Why Haemonetics (HAE) is a Strong Value Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-11-12 12:45:58 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Haemonetics (HAE) Could Surge 25.58%: Read This Before Placing a Bet |
The mean of analysts' price targets for Haemonetics (HAE) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-11-11 13:00:37 |
Czytaj oryginał (ang.) |
| Haemonetics' Q2 Earnings and Revenues Top, Stock Up, Margins Expand |
HAE delivers impressive growth in the top and bottom lines in the second quarter of fiscal 2025. |
zacks.com |
2024-11-11 11:01:15 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Haemonetics (HAE) Q2 Earnings: A Look at Key Metrics |
The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-11-07 12:35:57 |
Czytaj oryginał (ang.) |
| Haemonetics (HAE) Tops Q2 Earnings and Revenue Estimates |
Haemonetics (HAE) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $0.99 per share a year ago. |
zacks.com |
2024-11-07 10:26:11 |
Czytaj oryginał (ang.) |
| Haemonetics 2nd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website |
Financial release accessible online BOSTON , Nov. 7, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2025, which ended September 28, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. |
prnewswire.com |
2024-11-07 08:00:00 |
Czytaj oryginał (ang.) |
| Haemonetics (HAE) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures |
Beyond analysts' top -and-bottom-line estimates for Haemonetics (HAE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024. |
zacks.com |
2024-11-06 12:20:25 |
Czytaj oryginał (ang.) |